Clinical Trial

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?
Trial Details
NCT Number NCT07284277
Lead Sponsor Clinica Universidad de Navarra, Universidad de Navarra
Conditions Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma
Enrollment 30 participants
Start Date 2025-10-14
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-16